External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data

por Kassir, Nastya, Chan, Phyllis, Dang, Steve, Bruno, René
Publicado 2023

A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain

por Mercier, François, Claret, Laurent, Prins, Klaas, Bruno, René
Publicado 2014

Update to improve reproducibility and interpretability: A response to “Machine Learning for Tumor Growth Inhibition”

por Chan, Phyllis, Lu, James, Bruno, René, Jin, Jin Y.
Publicado 2022

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

por Han, Kelong, Claret, Laurent, Sandler, Alan, Das, Asha, Jin, Jin, Bruno, Rene
Publicado 2016

Application of Machine Learning for Tumor Growth Inhibition – Overall Survival Modeling Platform

por Chan, Phyllis, Zhou, Xiaofei, Wang, Nina, Liu, Qi, Bruno, René, Jin, Jin Y.
Publicado 2020

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel

por Krishnan, Sreenath M., Friberg, Lena E., Bruno, René, Beyer, Ulrich, Jin, Jin Y., Karlsson, Mats O.
Publicado 2021

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

por Netterberg, Ida, Bruno, René, Chen, Ya‐Chi, Winter, Helen, Li, Chi‐Chung, Jin, Jin Y., Friberg, Lena E.
Publicado 2020

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework

por Chan, Phyllis, Marchand, Mathilde, Yoshida, Kenta, Vadhavkar, Shweta, Wang, Nina, Lin, Alyse, Wu, Benjamin, Ballinger, Marcus, Sternheim, Nitzan, Jin, Jin Y., Bruno, René
Publicado 2021

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

por Shemesh, Colby S., Chan, Phyllis, Legrand, Fatema A., Shames, David S., Das Thakur, Meghna, Shi, Jane, Bailey, Lorna, Vadhavkar, Shweta, He, Xian, Zhang, Wei, Bruno, René
Publicado 2020

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)

por Peters, Solange, Galle, Peter R., Bernaards, Coen A., Ballinger, Marcus, Bruno, René, Quarmby, Valerie, Ruppel, Jane, Vilimovskij, Alexandr, Wu, Benjamin, Sternheim, Nitzan, Reck, Martin
Publicado 2021

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

por Moein, Anita, Lu, Tong, Jönsson, Siv, Ribbing, Jakob, Kassir, Nastya, Zhang, Wenhui, Sperinde, Gizette, Zhang, Rong, Tang, Meina, Oh, Young S., Bruno, Rene, Zhu, Rui
Publicado 2022

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

por Morrissey, Kari M., Marchand, Mathilde, Patel, Hina, Zhang, Rong, Wu, Benjamin, Phyllis Chan, H., Mecke, Almut, Girish, Sandhya, Jin, Jin Y., Winter, Helen R., Bruno, René
Publicado 2019

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

por Shemesh, Colby S., Chanu, Pascal, Jamsen, Kris, Wada, Russ, Rossato, Gianluca, Donaldson, Francis, Garg, Amit, Winter, Helen, Ruppel, Jane, Wang, Xin, Bruno, Rene, Jin, Jin, Girish, Sandhya
Publicado 2019

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)

por Wu, Benjamin, Sternheim, Nitzan, Agarwal, Priya, Suchomel, Julia, Vadhavkar, Shweta, Bruno, Rene, Ballinger, Marcus, Bernaards, Coen A., Chan, Phyllis, Ruppel, Jane, Jin, Jin, Girish, Sandhya, Joshi, Amita, Quarmby, Valerie
Publicado 2021